Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Probiotics in the Prevention of Complications After Colorectal Surgery

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02313519
Recruitment Status : Completed
First Posted : December 10, 2014
Last Update Posted : December 10, 2014
Sponsor:
Collaborator:
Aristotle University Of Thessaloniki
Information provided by (Responsible Party):
Evangelos J. Giamarellos-Bourboulis, M.D., University of Athens

Brief Summary:
Based on the need of large-scale, trials to explore the use of probiotics to reduce post-operative complication rate, a randomized controlled trial is designed to investigate the impact of a probiotics treatment protocol on postoperative morbidity in an open elective colonic surgery cohort. The major objective is reduction of post-operative complications after 30 days.

Condition or disease Intervention/treatment Phase
Postoperative Complications Dietary Supplement: Probiotics Dietary Supplement: Placebo Phase 4

Detailed Description:
Major colorectal surgery, i.e. surgery involving a wide colon resection and/or a very low anastomosis, remains problematic, despite great advances in medico-pharmaceutical treatment, improvement in surgical techniques, and sophisticated postoperative management. Such surgery is still accompanied by an unacceptably high morbidity of 15% to 23.2% leading to an increase in the number of ventilatory support days, prolongation of total hospital stay, significantly higher medical costs, patient suffering, and, unfortunately mortality. Worse than this, nowadays, infections and sepsis are by far the most common morbidities, either as initial cause or as a consequence of another complication, such as anastomotic leakage. Ongoing clinical studies have reported probiotic therapies to be beneficial in elective surgery cases, since they have been shown to successfully modulate the GI flora in a plethora of medical settings and in critically ill and trauma patients. More precisely, recent randomized controlled studies and meta-analyses in elective surgery and abdominal surgery patients have demonstrated that the perioperative use of probiotics is safe and reduces both the incidence of postoperative wound infections, sepsis, post-operative pneumonia and other infections, and the necessary duration of hospital stay and length of antibiotic therapy. However, there exist few controlled, large-scale, trials comparing the current standard treatment with the probiotic concept and showing the superiority of the latter in colonic surgery with regard to a reduced complication rate. Therefore, the investigators decided to conduct a randomized controlled trial to investigate the impact of a probiotics treatment protocol on postoperative morbidity in an open elective colonic surgery cohort. The major objective is to evidence a reduction in 30-day infectious, surgery-related morbidity: any surgical site infection; organ specific infections; systemic infections and anastomotic leakage. Minor objectives related to the reduction in other non-infectious complications, as well as the assessment of outcome indicators such as the number of days in postoperative ileus, on mechanical ventilation, stay in ICU, total hospitalization and mortality in the 30-day post-operative period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 164 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: A Randomized Clinical Study of the Efficacy of a Formulation of Four Probiotics for the Prevention of Post-operative Complications in Patients Undergoing Colorectal Surgery
Study Start Date : April 2013
Actual Primary Completion Date : July 2014
Actual Study Completion Date : August 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: After Surgery

Arm Intervention/treatment
Placebo Comparator: Placebo
Capsules of powdered glucose polymer given one capsule every 12 hours for 15 days
Dietary Supplement: Placebo
Glucose powder
Other Name: Placebo capsules

Active Comparator: Probiotics
Capsules containing Lactobacillus acidophilus LA-5 [1.75x10^9 cfu], Lactobacillus plantarum [0.5x10^9 cfu], Bifidobacterium lactis BB-12 [1.75x10^9cfu], and Saccharomyces boulardii [1.5x10^9] per capsule. One capsule is given every 12 hours for 15 days
Dietary Supplement: Probiotics
Probiotics are prepared in capsule form
Other Name: Lactobacillus, Bifidobacterium and Saccharomyces boulardii




Primary Outcome Measures :
  1. Postoperative complications [ Time Frame: 30 days ]
    The total of postoperative complications observes in each study group. These comprise: any anastomotic leakage; abdominal wound infection and dehiscence; organ specific infections, such as pneumonia, urinary tract and central vein port-site infections, and systemic infections [bacteraemia, fungal infections] as regularly defined by positive cultures, radiograms, increased white blood cell count or purulent material discharge; sepsis and septic shock


Secondary Outcome Measures :
  1. Minor complications [ Time Frame: 30 days ]
    Rate of minor events in each group. These comprise peripheral vein thrombosis or pulmonary embolism and cardio-pulmonary or renal insufficiency. Moreover, the number of days on mechanical ventilation, in postoperative ileus, of total hospitalization, as well as 30-day mortality is taken into account.

  2. Cytokine levels [ Time Frame: 4 days ]
    Measurement of serum cytokines in subgroups of patients

  3. Cytokine gene transcripts [ Time Frame: 4 days ]
    Measurement of gene transcripts in whole blood in subgroups of patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent
  • Acceptable nutritional status and programmed for open surgery for colorectal cancer.
  • Operation by the same consultant either as surgeon or as the primary assistant.

Exclusion Criteria:

  • Inability to provide written informed consent
  • The need only for emergency or palliative surgery
  • American Society of Anaesthesiologists (ASA) class of IV
  • Pregnancy or lactation
  • Inflammatory bowel disease
  • Use of antibiotics during the last 10 days before surgery
  • Recent steroid therapy or preoperative neoadjuvant chemotherapy or radiotherapy
  • Pre-existing signs of bacterial [white cell count, body temperature] or viral infection [hepatitis B or C, human immunodeficiency virus, cytomegalovirus].

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02313519


Sponsors and Collaborators
Evangelos J. Giamarellos-Bourboulis, M.D.
Aristotle University Of Thessaloniki
Investigators
Layout table for investigator information
Study Chair: Katerina Kotxampassi, MD, PhD AXEPA University of Thessaloniki, 1st Department of Propedeutic Surgery, Thessaloniki, Greece
Principal Investigator: Evangelos Giamarellos-Bourboulis, MD, PhD University of Athens, 4th Department of Internal Medicine, Athens, Greece

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Evangelos J. Giamarellos-Bourboulis, M.D., Associate Professor of Medicine, University of Athens
ClinicalTrials.gov Identifier: NCT02313519     History of Changes
Other Study ID Numbers: LACT002
First Posted: December 10, 2014    Key Record Dates
Last Update Posted: December 10, 2014
Last Verified: December 2014
Keywords provided by Evangelos J. Giamarellos-Bourboulis, M.D., University of Athens:
Infections
anastomotic leakage
Additional relevant MeSH terms:
Layout table for MeSH terms
Postoperative Complications
Pathologic Processes